Comparison of Diagnostic Sensitivity and Quantitative Indices Between 68Ga-DOTATOC PET/CT and 111In-Pentetreotide SPECT/CT in Neuroendocrine Tumors: a Preliminary Report

被引：30

作者：

Lee I. ^{[1
]}

Paeng J.C. ^{[1
]}

Lee S.J. ^{[1
]}

Shin C.S. ^{[2
]}

Jang J.-Y. ^{[3
]}

Cheon G.J. ^{[1
,4
]}

Lee D.S. ^{[1
,5
]}

Chung J.-K. ^{[1
,4
]}

Kang K.W. ^{[1
,4
]}

机构：

[1] Department of Nuclear Medicine, Seoul National University College of Medicine, 101 Daehak-ro, Jongno-gu, Seoul

[2] Department of Internal Medicine, Seoul National University College of Medicine, Seoul

[3] Department of Surgery, Seoul National University College of Medicine, Seoul

[4] Cancer Research Institute, Seoul National University, Seoul

[5] Department of Molecular Medicine and Biopharmaceutical Sciences, Graduate School of Convergence Science and Technology, Seoul National University, Gyeonggi-Do

来源：

Nuclear Medicine and Molecular Imaging | 2015年 / 49卷 / 4期

基金：

新加坡国家研究基金会;

关键词：

!sup]111[!/sup]In-pentetreotide; !sup]68[!/sup]Ga-DOTATOC; Neuroendocrine tumors; Positron emission tomography; Single-photon emission-computed tomography;

D O I：

10.1007/s13139-015-0356-y

中图分类号：

学科分类号：

摘要：

Purpose: In-pentetreotide has been used for neuroendocrine tumors expressing somatostatin receptors. Recently, 68Ga-DOTATOC PET has been used with the advantage of high image quality. In this study, we compared quantitative indices between 111In-pentetreotide SPECT/CT and 68Ga-DOTATOC PET/CT. Methods: Thirteen patients diagnosed with neuroendocrine tumors were prospectively recruited. Patients underwent 111In-pentetreotide scans with SPECT/CT and 68Ga-DOTATOC PET/CT before treatment. The number and location of lesions were analyzed on both imaging techniques to compare lesion detectability. Additionally, the maximal uptake count of each lesion and mean uptake count of the lungs were measured on both imagings, and target-to-normal lung ratios (TNR) were calculated as quantitative indices. Results: Among 13 patients, 10 exhibited lesions with increased uptake on 111In-pentetreotide SPECT/CT and/or 68Ga-DOTATOC PET/CT. Scans with SPECT/CT detected 19 lesions, all of which were also detected on PET/CT. Moreover, 16 additional lesions were detected on PET/CT (6 in the liver, 9 in the pancreas and 1 in the spleen). PET/CT exhibited a significantly higher sensitivity than SPECT/CT (100 % vs. 54 %, P < 0.001). TNR was significantly higher on PET/CT than on SPECT/CT (99.9 ± 84.3 vs. 71.1 ± 114.9, P < 0.001) in spite of a significant correlation (r = 0.692, P = 0.01). Conclusion: Ga-DOTATOC PET/CT has a higher diagnostic sensitivity than 111In-pentetreotide scans with SPECT/CT. The TNR on PET/CT is higher than that of SPECT/CT, which also suggests the higher sensitivity of PET/CT. 111In-pentetreotide SPECT/CT should be used carefully if it is used instead of 68Ga-DOTATOC PET/CT. © 2015, Korean Society of Nuclear Medicine.

引用

页码：284 / 290

页数：6

共 28 条

[1]

Barbieri F., Albertelli M., Grillo F., Mohamed A., Saveanu A., Barlier A., Et al., Neuroendocrine tumors: insights into innovative therapeutic options and rational development of targeted therapies, Drug Discov Today, 19, 4, pp. 458-468, (2014)

[2]

Treglia G., Castaldi P., Rindi G., Giordano A., Rufini V., Diagnostic performance of Gallium-68 somatostatin receptor PET and PET/CT in patients with thoracic and gastroenteropancreatic neuroendocrine tumours: a meta-analysis, Endocrine, 42, 1, pp. 80-87, (2012)

[3]

Hauso O., Gustafsson B.I., Kidd M., Waldum H.L., Drozdov I., Chan A.K., Et al., Neuroendocrine tumor epidemiology: contrasting Norway and North America, Cancer, 113, 10, pp. 2655-2664, (2008)

[4]

Fraenkel M., Kim M., Faggiano A., de Herder W.W., Valk G.D., Incidence of gastroenteropancreatic neuroendocrine tumours: a systematic review of the literature, Endocr Relat Cancer, 21, 3, pp. R153-R163, (2014)

[5]

Krausz Y., Keidar Z., Kogan I., Even-Sapir E., Bar-Shalom R., Engel A., Et al., SPECT/CT hybrid imaging with 111In-pentetreotide in assessment of neuroendocrine tumours, Clin Endocrinol (Oxf), 59, 5, pp. 565-573, (2003)

[6]

Naswa N., Sharma P., Soundararajan R., Karunanithi S., Nazar A.H., Kumar R., Et al., Diagnostic performance of somatostatin receptor PET/CT using 68Ga-DOTANOC in gastrinoma patients with negative or equivocal CT findings, Abdom Imaging, 38, 3, pp. 552-560, (2013)

[7]

Buchmann I., Henze M., Engelbrecht S., Eisenhut M., Runz A., Schafer M., Et al., Comparison of 68Ga-DOTATOC PET and 111In-DTPAOC (Octreoscan) SPECT in patients with neuroendocrine tumours, Eur J Nucl Med Mol Imaging, 34, 10, pp. 1617-1626, (2007)

[8]

Hoyer D., Bell G.I., Berelowitz M., Epelbaum J., Feniuk W., Humphrey P.P., Et al., Classification and nomenclature of somatostatin receptors, Trends Pharmacol Sci, 16, 3, pp. 86-88, (1995)

[9]

Kubota K., Okasaki M., Minamimoto R., Miyata Y., Morooka M., Nakajima K., Et al., Lesion-based analysis of 18F-FDG uptake and 111In-pentetreotide uptake by neuroendocrine tumors, Ann Nucl Med, 28, 10, pp. 1004-1010, (2014)

[10]

Etchebehere E.C., de Oliveira S.A., Gumz B., Vicente A., Hoff P.G., Corradi G., Et al., 68Ga-DOTATATE PET/CT, 99mTc-HYNIC-octreotide SPECT/CT, and whole-body MR imaging in detection of neuroendocrine tumors: a prospective trial, J Nucl Med, 55, 10, pp. 1598-1604, (2014)

← 1 2 3 →